Related Experiment Videos
[Vaccine therapy in the treatment of nasal and sinus bacterial allergies]
1Klinicznego Oddziału Otolaryngologicznego Wojskowego Szpitala Klinicznego w Bydgoszczy.
Insights
Bacterial vaccines significantly improved nasal and sinus allergies in children. Combined therapy, including vaccines and anti-inflammatory drugs, yielded the best clinical outcomes compared to no vaccine treatment.
Area of Science:
- Immunology
- Pediatrics
- Allergology
Context:
- Nasal and sinus bacterial allergies affect numerous children.
- Bacterial vaccine therapy has been explored as a treatment option.
Purpose:
- To analyze the effectiveness of bacterial vaccines in treating nasal and sinus bacterial allergies in children.
- To compare outcomes of vaccine therapy with a control group.
Summary:
- A study analyzed 160 children treated with bacterial vaccines (Polyvaccium, Broncho-Vaxom, IRS-19) between 1981-1990.
- Positive outcomes included improved clinical manifestations, normalized immunoglobulin levels, and reduced allergic reactions.
- Combined therapy (vaccine, anti-inflammatory, antiallergic) achieved 68% positive results, significantly better than the control group (no vaccine therapy).
Impact:
- Bacterial vaccine therapy, particularly combined with other treatments, demonstrates significant efficacy in managing pediatric nasal and sinus bacterial allergies.
- Findings support the use of bacterial vaccines as a viable therapeutic strategy in pediatric allergy management.
Abstract:
An analysis was performed of the course of nasal and sinus bacterial allergy in 160 children treated in the years 1981-1990 with bacterial vaccines. History data, results of medical examinations and laboratory investigations, indications and contraindications to vaccine therapy, and the methods and results of treatment are presented. Vaccines available in Poland were used--Polyvaccium (nasal and subcutaneous) produced by Biomed, Broncho-Vaxom, IRS-19. As the main criterion of positive results, improvement or regression of clinical manifestations, normalization of immunoglobulin level, and also extinction of organ reactions and generalized and local skin reactions to bacterial allergens, were accepted. Very good and good results were achieved in 63% of the studied patients. The best results were achieved using combined treatment--vaccine therapy, anti-inflammatory drugs, and symptomatic antiallergic treatment (68% of positive results). In comparison to the control group (80 children) in which no vaccine therapy was used, the results obtained in the studied group were statistically significantly better.